Eventide Asset Management - AIMMUNE THERAPEUTICS INC ownership

Quarter-by-quarter ownership
Eventide Asset Management ownership history of AIMMUNE THERAPEUTICS INC
ValueSharesWeighting
Q2 2020$53,357,000
-3.9%
3,193,117
-17.1%
1.16%
-35.5%
Q1 2020$55,531,000
-46.2%
3,851,000
+24.9%
1.80%
-38.2%
Q4 2019$103,221,000
+59.8%
3,084,0000.0%2.91%
+36.3%
Q3 2019$64,579,000
+11.8%
3,084,000
+11.1%
2.13%
+21.5%
Q2 2019$57,776,000
+31.8%
2,775,000
+41.4%
1.76%
+16.4%
Q1 2019$43,851,000
+5.4%
1,962,000
+12.8%
1.51%
-18.1%
Q4 2018$41,597,000
-12.3%
1,739,0000.0%1.84%
+5.7%
Q3 2018$47,440,000
+8.9%
1,739,000
+7.3%
1.74%
-3.7%
Q2 2018$43,562,000
-12.5%
1,620,000
+3.5%
1.81%
-22.5%
Q1 2018$49,813,000
+7.4%
1,564,983
+27.6%
2.33%
-3.5%
Q4 2017$46,367,000
+81.6%
1,226,000
+19.0%
2.42%
+67.0%
Q3 2017$25,534,000
+20.6%
1,030,0000.0%1.45%
+9.8%
Q2 2017$21,177,000
+214.4%
1,030,000
+232.3%
1.32%
+195.5%
Q1 2017$6,736,000310,0000.45%
Other shareholders

There were no reported owners of AIMMUNE THERAPEUTICS INC in Q3 2023.

NameSharesValueWeighting ↓
View complete list of AIMMUNE THERAPEUTICS INC shareholders